Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Inks Deals to Increase Patient Access to VeriStrat Test

NEW YORK (GenomeWeb News) – Biodesix today announced two partnerships to increase patient access to its VeriStrat molecular diagnostic test for non-small cell lung cancer.

The deals are with Concentra, a subsidiary of managed care organization Humana, and with Hooper Holmes Health and Wellness, a provider of various medical exam and data services.

Biodesix's deal with Concentra will allow patients access to more than 300 Concentra medical centers and laboratories across the US for collection of blood samples, while the agreement with Hooper Holmes Health and Wellness gives patients the option to have their blood collected in their own homes or at a location of choice by certified phlebotomists from Hooper Holmes' network of more than 9,000 local healthcare professionals.

The VeriStrat is a serum proteomic test aimed at helping physicians guide treatment of patients with NSCLC. Blood samples are processed at Biodesix's CLIA accredited central laboratory, and the firm said results are typically reported within 72 hours.

"Working with Hooper Holmes and Concentra will help to ensure that more patients have access to VeriStrat testing as our test volumes continue to increase," Doug Swan, vice president of commercial operations for Biodesix, said in a statement.

Financial and other terms of the deals were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.